A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to …
CONTEXT: Several randomized controlled trials (RCTs) on phosphodiesterase type 5
inhibitors (PDE5-Is) have showed significant improvements in both lower urinary tract …
inhibitors (PDE5-Is) have showed significant improvements in both lower urinary tract …
Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction
KE Andersson - Pharmacological reviews, 2011 - ASPET
Erection is basically a spinal reflex that can be initiated by recruitment of penile afferents,
both autonomic and somatic, and supraspinal influences from visual, olfactory, and …
both autonomic and somatic, and supraspinal influences from visual, olfactory, and …
Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised …
BACKGROUND: Tadalafil improved lower urinary tract symptoms (LUTS) suggestive of
benign prostatic hyperplasia (BPH; LUTS/BPH) in clinical studies but has not been …
benign prostatic hyperplasia (BPH; LUTS/BPH) in clinical studies but has not been …
Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia
M Gacci, I Eardley, F Giuliano, D Hatzichristou… - European urology, 2011 - Elsevier
CONTEXT: This review focuses on the relationship among sexual dysfunction (SD), lower
urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH), and related …
urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH), and related …
Current and emerging pharmacological targets and treatments of urinary incontinence and related disorders
MC Michel, L Cardozo, CJ Chermansky, F Cruz… - Pharmacological …, 2023 - ASPET
Overactive bladder syndrome with and without urinary incontinence and related conditions,
signs, and disorders such as detrusor overactivity, neurogenic lower urinary tract …
signs, and disorders such as detrusor overactivity, neurogenic lower urinary tract …
Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism (s) of action
Background The PDE5 inhibitor tadalafil is investigation for the treatment of lower urinary
tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). Several clinical …
tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). Several clinical …
Benign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunctions
Metabolic syndrome (MetS) is a well‐recognized cluster of cardiovascular (CV) risk factors
including obesity, hypertension, dyslipidemia, and hyperglycaemia, closely associated with …
including obesity, hypertension, dyslipidemia, and hyperglycaemia, closely associated with …
Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously …
A Morelli, E Sarchielli, P Comeglio… - The journal of sexual …, 2011 - academic.oup.com
Introduction In humans, prostate phosphodiesterase type 5 inhibitors (PDE5) expression
was prominently localized in the endothelial and smooth muscle cells of the vascular bed …
was prominently localized in the endothelial and smooth muscle cells of the vascular bed …
PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS
L Vignozzi, M Gacci, I Cellai, A Morelli… - The …, 2013 - Wiley Online Library
BACKGROUND Metabolic syndrome (MetS) and benign prostate hyperplasia (BPH)/low
urinary tract symptoms (LUTS) are often comorbid. Chronic inflammation is one of the …
urinary tract symptoms (LUTS) are often comorbid. Chronic inflammation is one of the …
Latest evidence on the use of phosphodiesterase type 5 inhibitors for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia
M Gacci, KE Andersson, C Chapple, M Maggi… - European urology, 2016 - Elsevier
Context Several preclinical reports, randomized controlled trials, systematic reviews, and
posthoc analyses corroborate the role of phosphodiesterase type 5 inhibitors (PDE5-Is) in …
posthoc analyses corroborate the role of phosphodiesterase type 5 inhibitors (PDE5-Is) in …